Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update

Syndax reported 3Q26 total revenue of $83.3 million, up 82% year over year. Revuforj net revenue rose 90% to $60.7 million, with new patients up 20% quarter over quarter; Niktimvo net revenue increased 47% to $67.4 million, generating $22.6 million in Syndax collaboration revenue. New revumenib data from clinical trials and real-world studies are expected in 4Q26.

Analysis

The key underwriting distinction is that Niktimvo’s $67.4m of product sales are not equivalent to Syndax revenue: the release reports $22.6m of collaboration revenue, while Revuforj contributes $60.7m. Thus the reported top line is currently much more directly exposed to Revuforj adoption than the combined product-sales figures suggest. The 20% q/q increase in new Revuforj patients is a constructive demand signal, but it does not establish persistence, treatment duration, net pricing, or conversion into recurring revenue. Verify those metrics on the call.

Near term, the 4:30 p.m. ET call and 4Q26 revumenib updates are the catalysts; a positive headline may already be reflected in the optimistic framing, while safety, durability, or slower uptake would challenge it. Over 6–18 months, broader data could expand the addressable acute-leukemia population, but could also sharpen competition from other menin-inhibitor programs, including Kura Oncology’s, and pressure share or pricing. The release provides no basis to assess earnings quality, cash runway, valuation, or the economics of the Niktimvo collaboration. Treat the growth rates as promising operating evidence, not yet as proof of attractive unit economics.

Key Decisions for Investors

• Do not chase SNDX solely on the release. Use today’s call to verify Revuforj treatment duration, net pricing/reimbursement, repeat prescribing, and whether new-patient growth is translating into sustained revenue.
• Conditional trade: consider a small, defined-risk SNDX long only if management supports continued adoption and the 4Q26 data timetable without a material safety or execution concern. Set a thesis stop at evidence of slowing new-patient additions or a meaningful guidance/timetable setback; avoid sizing before reviewing valuation and cash runway.
• Track 4Q26 revumenib data as the main 1–3 month catalyst. Positive efficacy and tolerability across additional subtypes could improve the longer-term revenue opportunity; weak or narrow results would undermine the expansion case and increase competitive risk.
• Before underwriting Niktimvo as a second growth engine, confirm the collaboration revenue mechanics and Syndax’s retained economics. The product-sales figure alone does not establish the financial contribution to SNDX.